Suppr超能文献

99mTc-司他米比单光子发射计算机断层扫描在准确筛选原发性甲状旁腺功能亢进患者以进行微创放射性引导手术中的作用。

Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery.

作者信息

Rubello Domenico, Massaro Arianna, Cittadin Silvia, Rampin Lucia, Al-Nahhas Adil, Boni Giuseppe, Mariani Giuliano, Pelizzo Maria Rosa

机构信息

Nuclear Medicine Service - PET Unit, S. Maria della Misericordia Hospital, Istituto Oncologico Veneto, Viale Tre Martiri, 140, 45100 Rovigo, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1091-4. doi: 10.1007/s00259-006-0162-y. Epub 2006 Jun 28.

Abstract

PURPOSE

A prerequisite for optimum minimally invasive radio-guided surgery (MIRS) for primary hyperparathyroidism (PHPT) is the demonstration of significant uptake of (99m)Tc-sestamibi in a parathyroid adenoma (PA). The aim of this study was to evaluate the clinical role or (99m)Tc-sestamibi SPECT in selecting patients for this procedure.

METHODS

Fifty-four consecutive PHPT patients were evaluated by single-session (99m)Tc-pertechnetate/(99m)Tc-sestamibi planar subtraction scintigraphy, followed by (99m)Tc-sestamibi SPECT acquisition to localise hyperfunctioning PAs and assist in planning the surgical approach.

RESULTS

Scintigraphy showed the presence of a solitary PA in 47/54 patients (87%) and two or more PAs in four patients (7.4%); it was negative in the remaining three patients (5.6%). The overall sensitivity of (99m)Tc-sestamibi scintigraphy was 94.6%. In 7/54 patients, the PA was located deep in the para-oesophageal/paratracheal space. So far, 22 patients with scintigraphic evidence of a solitary PA (in four of whom the PA was located deep in the neck) have undergone successful MIRS using the low 37 MBq (1 mCi) (99m)Tc-sestamibi dose protocol. Intraoperative quick parathyroid hormone (QPTH) assay demonstrated a fall in all 22 patients, thus confirming successful removal of the hyperfunctioning PA. No major surgical complications were observed. After a period of follow-up ranging between 6 and 27 months (median 13 months), no case of persistent/recurrent PHPT was recorded. When comparing the parathyroid to background (P/B) ratio measured at planar and SPECT preoperative scintigraphy with that measured intraoperatively with the gamma probe, a good linear correlation was found between the SPECT and the intraoperative gamma probe measurements (r=0.89; p<0.01) but no correlation was found with planar scintigraphic data.

CONCLUSION

Our preliminary data suggest that measurement of the P/B ratio by means of (99m)Tc-sestamibi SPECT is more accurate in predicting the intraoperative measurements with the gamma probe. In this respect, a preoperative (99m)Tc-sestamibi SPECT acquisition should be recommended for better selection of PHPT patients in whom a MIRS approach can be offered.

摘要

目的

对于原发性甲状旁腺功能亢进症(PHPT)的最佳微创放射性引导手术(MIRS)而言,甲状旁腺腺瘤(PA)中(99m)锝-甲氧基异丁基异腈有显著摄取是一个前提条件。本研究的目的是评估(99m)锝-甲氧基异丁基异腈单光子发射计算机断层扫描(SPECT)在选择适合该手术的患者中的临床作用。

方法

对54例连续性PHPT患者进行单时段(99m)高锝酸盐/(99m)锝-甲氧基异丁基异腈平面减影闪烁显像,随后进行(99m)锝-甲氧基异丁基异腈SPECT采集,以定位功能亢进的PA并协助规划手术入路。

结果

闪烁显像显示47/54例患者(87%)存在单个PA,4例患者(7.4%)存在两个或更多PA;其余3例患者(5.6%)显像为阴性。(99m)锝-甲氧基异丁基异腈闪烁显像的总体敏感性为94.6%。在54例患者中的7例,PA位于食管旁/气管旁间隙深部。到目前为止,22例有单个PA闪烁显像证据的患者(其中4例PA位于颈部深部)已使用低37 MBq(1 mCi)(99m)锝-甲氧基异丁基异腈剂量方案成功进行了MIRS。术中快速甲状旁腺激素(QPTH)测定显示所有22例患者的QPTH均下降,从而证实功能亢进的PA已成功切除。未观察到重大手术并发症。在6至27个月(中位时间13个月)的随访期后,未记录到持续性/复发性PHPT病例。当比较术前平面和SPECT闪烁显像测量的甲状旁腺与本底(P/B)比值与术中用γ探头测量的比值时,发现SPECT与术中γ探头测量值之间存在良好的线性相关性(r = 0.89;p<0.01),但与平面闪烁显像数据无相关性。

结论

我们的初步数据表明,通过(99m)锝-甲氧基异丁基异腈SPECT测量P/B比值在预测术中γ探头测量值方面更准确。在这方面,对于可以提供MIRS手术的PHPT患者,建议术前进行(99m)锝-甲氧基异丁基异腈SPECT采集以更好地进行选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验